Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1369-1376

  Okada, Kohji ^a   Shimura, Tatsuo ^a   Suehiro, Taketoshi ^a   Mochiki, Erito ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Galectin 3; Gastric cancer; Prognosis; SNP; SSCP

Indexed keywords

GALECTIN 3; KI 67 ANTIGEN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; DNA MUTATIONAL ANALYSIS; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 33645811957     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Moutsatsos IK, Davis JM and Wang JL: Endogenous lectins from cultured cells: subcellular localization of carbohydrate-binding protein 35 in 3T3 fibroblasts. J Cell Biol 702: 477-483, 1986.
2. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu FT, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PWJ, Rini JM and Wang JL: Galectins: a family of animal beta-galactoside-binding lectins. Cell 76: 597-598, 1994.
3. Raz A, Pazerini G and Carmi P: Identification of the metastasis- associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein. Cancer Res 49: 3489-3493, 1989.
4. Cherayil BJ, Weiner SJ and Pillai S: The Mac-2 antigen is a galactose-specific lectin that binds IgE. J Exp Med 770: 1959-1972, 1989.
5. Hsu DK, Zuberi RI and Liu FT: Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem 267: 14167-14174, 1992.
6. Massa SM, Cooper DN, Leffler H and Barondes SH: L-29, an endogenous lectin, binds to glycoconjugate ligands with positive cooperativity. Biochemistry 32: 260-267, 1993.
7. Kadrofske MM, Openo KP and Wang JL: The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 349: 7-20, 1998.
8. Ochieng J, Gerold M and Raz A: Dichotomy in the laminin-binding properties of soluble and membrane-bound human galactoside-binding protein. Biochem Biophys Res Commun 186: 1674-1680, 1992.
9. Inohara H and Raz A: Identification of human melanoma cellular and secreted ligands for galectin-3. Biochem Biophys Res Commun 207: 1366-1375, 1994.
10. Bresalier RS, Byrd JC, Wang L and Raz A: Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. Cancer Res 56: 4354-4357, 1996.
11. Lin HM, Pestell RG, Raz A and Kim HR: Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 21: 8001-8010, 2002.
12. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of beta-catenin. Cancer Res 64: 6363-6367, 2004.
13. Schoeppner HL, Raz A, Ho SB and Bresalier RS: Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75: 2818-2826, 1995.
14. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A and Kubo T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6: 4635-4640, 2000.
15. van den Brule FA, Waltregny D, Liu FT and Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89: 361-367, 2000.
16. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, Tanaka K, Sekihara H and Hirohashi S: Clinico-pathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8: 2570-2575, 2002.
17. Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L and Ranelletti FO: Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeaKogal squamous-cell carcinoma. J Clin Oncol 20: 3850-3856, 2002.
18. Endo K, Kohnoe S, Tsujita E, Watanaba A, Nakashima H, Baba H and Maehara Y: Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 25: 3117-3121, 2005.
19. Liu XP, Oga A, Suehiro Y, Furuya T, Kawauchi S and Sasaki K: Inverse relationship between matrilysin expression and proliferative activity of cells in advanced gastric carcinoma. Hum Pathol 33: 741-747, 2002.
20. Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU and Kimura ET: Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab 87: 4806-4810, 2002.
21. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D and Tahara E: Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56: 474-480, 1994.
22. Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, Itoh K and Miura S: Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9: 1307-1312, 2002.
23. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, Hanisch FG, Monig SP, Schroder W, Flucke U, Thiele J, Holscher AH and Dienes HP: Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol 21: 258-266, 2000.
24. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A and Campo E: Differential expression of galectin-3 and galectin-1 in colorectal cancer progression. Gastroenterology 113: 1906-1915, 1997.
25. van den Brule FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME and Castronovo V: Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30: 1096-1099, 1994.
26. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS and Raz A: The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59: 6239-6245, 1999.
27. Mazurek N, Conklin J, Byrd JC, Raz A and Bresalier RS: Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J Biol Chem 275: 36311-36315, 2000.
28. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR and Raz A: Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277: 6852-6857, 2002.
29. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS and Raz A: Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24: 4395-4406, 2004.